Breathe Well Live Well
|
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of …
News-Medical.net Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) … Teva Gets Approval To Market DuoResp Spiromax In Europe |
View full post on asthma – Google News
|
AB Science Announces That FDA Authorization (IND) Has Been Granted for the …
EON: Enhanced Online News (press release) For the record, severe persistent asthma uncontrolled with oral corticosteroids is a disease that has no registered treatment and all the immunosuppressant and biologic drugs tested to date have failed. Masitinib is therefore the only drug candidate in … |
View full post on asthma – Google News
|
AB Science Announces That FDA Authorization (IND) Has Been Granted for the …
MarketWatch (press release) For the record, severe persistent asthma uncontrolled with oral corticosteroids is a disease that has no registered treatment and all the immunosuppressant and biologic drugs tested to date have failed. Masitinib is therefore the only drug candidate in … |
View full post on asthma – Google News